Krebs Biochemicals Reports Q2 Loss of Rs 5.4 Crore

Revenue stood at Rs 5.79 crore for the quarter, with a net loss of Rs 5.40 crore recorded.

Reader Takeaway: Revenue improved year-on-year, but the Vizag plant closure and pending merger approval remain significant operational hurdles.

What just happened

Krebs Biochemicals & Industries Limited has announced its financial results for the quarter ended September 30, 2026. The company reported a net loss of Rs 5.40 crore, an improvement compared to the Rs 6.14 crore loss in the corresponding quarter last year. Revenue from operations saw a rise to Rs 5.79 crore against Rs 4.17 crore in the previous year's comparative period.

Why this matters

The company continues to face severe operational constraints. The manufacturing unit in Vizag remains shut following an order from the Andhra Pradesh Pollution Control Board issued in February 2025. This suspension significantly hampers the firm's ability to scale operations and generate meaningful revenue, keeping the stock's performance tethered to regulatory updates.

The backstory

In June 2026, the Board of Directors approved a scheme of amalgamation with Ipca Laboratories. This corporate restructuring is viewed as the primary long-term catalyst for shareholders. The scheme, with an appointed date of April 1, 2026, is currently awaiting necessary regulatory consents and shareholder approvals.

Risks to watch

Investors must monitor the status of the Vizag unit, as prolonged closure impacts ongoing financials. Furthermore, the amalgamation process involves multiple layers of approval; any delays or regulatory hurdles in this process could influence investor sentiment significantly.

What to track next

Key tracking points include updates on the dialogue with the Pollution Control Board regarding the Vizag unit and official filings regarding the NCLT or regulatory progress on the Ipca Laboratories merger.